he Seattle biotech Omeros (OMER) lost favorable Medicare reimbursement for its only approved product — a cataract surgery drug — at the end of last year, making it likely sales will plunge this year, according to a consultant to the company.

The favorable policy meant hospitals and surgery centers where Medicare patients go for cataract procedures received a separate reimbursement for the drug, Omidria, for three years. But that policy expired when the calendar clicked over to Jan. 1, said Kevin Corcoran, president of Corcoran Consulting Group and an expert on ophthalmology reimbursement issues. Omeros is a Corcoran client.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Why would one pay to read this? All of this was known since 01/01/18. Lol. This investigative reporting is a joke. 😂

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.